Table 1.
Cutaneous melanoma CTC studies included in this review.
| Author | Year | Multicenter | N | Blood Draw | CTC Enrichment/ Detection |
CTC Markers | AJCC Stage | Outcomes Related to CTC Detection |
|---|---|---|---|---|---|---|---|---|
| G Palmieri et al. [26] | 2006 | No | 149 | Multiple | MM PCR | MELTF, MLANA, TYR | I–III | Recurrence, Survival (DFS, OS) |
| CR Scoggins et al. [27] | 2006 | Yes | 820 | Multiple | MM PCR | MAGEA3, MLANA, PMEL, TYR | I, II | Survival (DDFS, DFS) |
| K Koyanagi et al. [28] | 2006 | No | 50 | Single | MM PCR | B4GALNT1, MAGEA3, MLANA | IV | Survival (OS, PFS), Treatment response |
| K Koyanagi et al. [29] | 2006 | No | 148 | Multiple | SM PCR | MITF | I–IV | AJCC Stage, Survival (OS, RFS) |
| E Carrillo et al. [30] | 2006 | No | 58 | Single | SM PCR | TYR | I-IV | AJCC Stage, Recurrence, Survival (OS) |
| P Quaglino et al. [31] | 2007 | No | 200 | Multiple | SM PCR | TYR | IV | Progression, Survival (OS, PFS), Treatment response |
| C Visús et al. [32] | 2007 | No | 114 | Single | SM PCR | TYR | I–IV | AJCC Stage, Survival (DFS, OS, PFS) |
| P Arenberger et al. [33] | 2008 | No | 65 | Multiple | MM PCR | MLANA, PMEL, MAGEA3, MIA, TYR | II–III | Progression |
| P Rutkowski et al. [34] | 2008 | No | 107 | Single | MM PCR | MLANA, TYR, uMAGE | III | None |
| A Fusi et al. [35] | 2009 | Yes | 299 | Multiple | MM PCR | MLANA, TYR | III | Progression |
| S Gkalpakiotis et al. [36] | 2010 | No | 65 | Multiple | MM PCR | MAGEA3, MIA, MLANA, PMEL, TYR | II, III | Progression, Survival (DFS) |
| K Koyanagi et al. [37] | 2010 | Yes | 87 | Multiple | MM PCR | B4GALNT1, MAGEA3, MITF, MLANA, PAX3, | IV | Progression, Survival (OS), Treatment response |
| I Samija et al. [38] | 2010 | No | 201 | Single | MM PCR | MITF, TYR | I-IV | Survival (OS, PFS) |
| C Rao et al. [39] | 2011 | No | 44 | Single | CELLSEARCH® | CD146, HMW-MAA | III, IV | Survival (OS) |
| S Hoshimoto et al. [40] | 2012 | Yes | 244 | Multiple | MM PCR | MAGEA3, MLANA, PAX3 | IV | Survival (DFS, OS) |
| S Hoshimoto et al. [41] | 2012 | Yes | 331 | Single | MM PCR | B4GALNT1, MAGEA3, MLANA | III | Survival (DDFS, DSS, RFS) |
| L Khoja et al. [42] | 2013 | No | 101 | Multiple | CELLSEARCH® | CD146, HMW-MAA | IV | Survival (OS) |
| AL Reid et al. [43] | 2013 | No | 230 | Multiple | MM PCR | ABCB5, MCAM, MLANA, PAX3, TGFB2, PAX3 | 0–IV | Recurrence, Treatment response |
| ES Gray et al. [44] | 2015 | No | 56 | Multiple | Flow cytometry | ABCB5, CD146, CD271, HMW-MAA, RANK | I–IV | Survival (PFS) |
| CL Roland et al. [45] | 2015 | No | 89 | Single | CELLSEARCH® | CD146, HMW-MAA | I–IV | AJCC Stage |
| J Li et al. [46] | 2018 | No | 100 | Multiple | CELLSEARCH® | CD146, HMW-MAA | I–IV | AJCC Stage, Survival (OS, PFS, DSS) |
| CS Hall et al. [47] | 2018 | No | 93 | Single | CELLSEARCH® | CD146, HMW-MAA | IV | Survival (PFS) |
| A Lucci et al. [48] | 2020 | No | 243 | Single | CELLSEARCH® | CD146, HMW-MAA | III | Survival (RFS) |
| SY Lin et al. [49] | 2020 | No | 75 | Multiple | ClearCell® FX/MM PCR | B4GALNT1, MAGEA3, MLANA, PAX3, TRP-AGG2-6 | III, IV | Survival (DFS, OS), Treatment response |
CTC: circulating tumor cell, N: number of patients, AJCC: The American Joint Committee on Cancer, MM PCR: Multi-marker reverse transcriptase-polymerase chain reaction, SM PCR: Single-marker reverse transcriptase-polymerase chain reaction, DFS: disease-free survival, OS: overall survival, DDFS: distant-disease free survival, PFS: progression-free survival, RFS: recurrence-free survival, DSS: disease-specific survival, HMW-MAA: high molecular weight melanoma-associated antigen, ABCB5: ATP binding cassette subfamily B member 5, RANK: receptor activator of nuclear factor kappa B. Official gene symbols approved by the HGNC (https://www.genenames.org/, accessed on 2 February 2022) are used for gene names.